Sign in or create an account to add this stock to your watchlist.
About Brainstorm Cell Therapeutics (NASDAQ:BCLI)
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival. It is developing NurOwn for various neurodegenerative diseases, including its lead indication, which is in Phase III clinical trial for the treatment of amyotrophic lateral sclerosis, as well as in preclinical trial for the treatment of multiple sclerosis, Parkinson's disease, Huntington's disease, and autism spectrum disorder. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BCLI
CUSIPN/A
Phone201-488-0460
Debt
Debt-to-Equity RatioN/A
Current Ratio1.41
Quick Ratio1.74
Price-To-Earnings
Trailing P/E Ratio-16.50
Forward P/E Ratio-7.53
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.20 per share
Price / Book21.45
Profitability
EPS (Most Recent Fiscal Year)($0.26)
Net Income$-4,950,000.00
Net MarginsN/A
Return on Equity-98.51%
Return on Assets-54.43%
Miscellaneous
Employees24
Outstanding Shares19,110,000
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Frequently Asked Questions
What is Brainstorm Cell Therapeutics' stock symbol?
Brainstorm Cell Therapeutics trades on the NASDAQ under the ticker symbol "BCLI."
How were Brainstorm Cell Therapeutics' earnings last quarter?
Brainstorm Cell Therapeutics (NASDAQ:BCLI) released its earnings results on Monday, May, 14th. The biotechnology company reported ($0.12) earnings per share for the quarter, topping analysts' consensus estimates of ($0.14) by $0.02. View Brainstorm Cell Therapeutics' Earnings History.
When is Brainstorm Cell Therapeutics' next earnings date?
What price target have analysts set for BCLI?
2 brokers have issued 1-year price objectives for Brainstorm Cell Therapeutics' shares. Their predictions range from $9.00 to $11.00. On average, they expect Brainstorm Cell Therapeutics' share price to reach $10.00 in the next twelve months. View Analyst Ratings for Brainstorm Cell Therapeutics.
What are Wall Street analysts saying about Brainstorm Cell Therapeutics stock?
Here are some recent quotes from research analysts about Brainstorm Cell Therapeutics stock:
- 1. HC Wainwright analysts commented, "We compare this to NurOwn. The drug not only has an established clean safety profile and convenient dosing, but also has the potential to be disease modifying, slowing down disease progression. This, coupled with orphan status for a 30K U.S. and 55K EU patient market, and we conclude there is real value in the company. We are initiating coverage of BCLI with a Buy rating and setting an $11 price target. The Phase 2 trial demonstrated proof of concept in ALS patients. The Phase 2 study, completed in July 2016, was a multi-center, double- blind, placebo-controlled trial in 48 ALS patients across three U.S. clinical sites. The endpoints in the trial were the change in the slope of Scale (ALSFRS- R) score and the change in Slow Vital Capacity (SVC) and muscle strength." (5/15/2018)
- 2. Maxim Group analysts commented, "BrainStorm announced the appointment of two more experts in the field of Neuroscience and Regenerative Medicine to the recently formed (March 12th) Scientific Advisory Board (SAB); Stanley Appel, MD and Amit Bar-Or, MD now join Jerold Chun, MD, PhD on the SAB (see their bios below). The SAB formed as a resource for scientific/medical expertise and guidance as Brainstorm executes the ongoing P3 study of NurOwn cells in ALS (Amyotrophic Lateral Sclerosis)." (3/21/2018)
Who are some of Brainstorm Cell Therapeutics' key competitors?
Some companies that are related to Brainstorm Cell Therapeutics include Cellular Biomedicine Group (CBMG), NanoString Technologies (NSTG), NantKwest (NK), Arsanis (ASNS), Osiris Therapeutics (OSIR), ADMA Biologics (ADMA), Fennec Pharmaceuticals (FENC), Organovo (ONVO), Compugen (CGEN), Pluristem Therapeutics (PSTI), Eiger Biopharmaceuticals (EIGR), Krystal Biotech (KRYS), Aptose Biosciences (APTO), Applied Genetic Technologies (AGTC) and Cidara Therapeutics (CDTX).
Who are Brainstorm Cell Therapeutics' key executives?
Brainstorm Cell Therapeutics' management team includes the folowing people:
- Dr. Irit Arbel DSc, Founder & Chairperson (Age 58)
- Mr. Chaim Lebovits, Pres & CEO (Age 47)
- Mr. Uri Yablonka, Exec. VP, Chief Bus. Officer & Director (Age 41)
- Mr. Eyal Rubin, Chief Financial Officer
- Dr. Ralph Z. Kern M.D., MHSc, COO & Chief Medical Officer (Age 60)
Has Brainstorm Cell Therapeutics been receiving favorable news coverage?
News headlines about BCLI stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Brainstorm Cell Therapeutics earned a news impact score of 0.15 on Accern's scale. They also assigned media headlines about the biotechnology company an impact score of 48.71 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
How do I buy shares of Brainstorm Cell Therapeutics?
Shares of BCLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Brainstorm Cell Therapeutics' stock price today?
One share of BCLI stock can currently be purchased for approximately $4.29.
How big of a company is Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics has a market capitalization of $81.99 million. The biotechnology company earns $-4,950,000.00 in net income (profit) each year or ($0.26) on an earnings per share basis. Brainstorm Cell Therapeutics employs 24 workers across the globe.
How can I contact Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics' mailing address is 1745 BROADWAY 17TH FLOOR, NEW YORK NY, 10019. The biotechnology company can be reached via phone at 201-488-0460 or via email at [email protected]
MarketBeat Community Rating for Brainstorm Cell Therapeutics (BCLI)
MarketBeat's community ratings are surveys of what our community members think about Brainstorm Cell Therapeutics and other stocks. Vote "Outperform" if you believe BCLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BCLI will underperform the S&P 500 over the long term. You may vote once every thirty days.
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
2 Wall Street analysts have issued ratings and price targets for Brainstorm Cell Therapeutics in the last 12 months. Their average twelve-month price target is $10.00, suggesting that the stock has a possible upside of 133.10%. The high price target for BCLI is $11.00 and the low price target for BCLI is $9.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $10.00 | $9.00 | $9.00 | $9.00 |
| Price Target Upside: | 133.10% upside | 192.21% upside | 204.05% upside | 122.77% upside |
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Consensus Price Target History
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 5/15/2018 | HC Wainwright | Initiated Coverage | Buy | $11.00 | High |  |
| 5/14/2018 | Maxim Group | Set Price Target | Buy | $9.00 | Low | |
(Data available from 5/20/2016 forward)
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Brainstorm Cell Therapeutics (NASDAQ BCLI) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 24.70%
Institutional Ownership Percentage: 9.56%
Brainstorm Cell Therapeutics (NASDAQ BCLI) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/15/2018 | June Sherie Almenoff | Director | Buy | 5,700 | $3.50 | $19,950.00 | | |
| 3/15/2018 | Ralph Dr. Kern | COO | Buy | 5,000 | $3.60 | $18,000.00 | | |
| 8/31/2017 | Irit Arbel | Director | Buy | 2,500 | $4.26 | $10,650.00 | 155,833 | |
| 8/23/2017 | Uri Yablonka | EVP | Buy | 2,000 | $3.98 | $7,960.00 | 7,543 | |
| 12/16/2015 | Robert G L Shorr | Director | Sell | 10,800 | $2.71 | $29,268.00 | 28,399 | |
| 12/15/2015 | Malcolm S. Taub | Director | Sell | 41,742 | $2.60 | $108,529.20 | 8,666 | |
| 12/11/2015 | Malcolm S. Taub | Director | Sell | 13,480 | $2.73 | $36,800.40 | 50,408 | |
| 10/1/2015 | International Holdings Ltd Acc | Major Shareholder | Buy | 2,000 | $2.58 | $5,160.00 | 138,806 | |
| 9/30/2015 | International Holdings Ltd Acc | Major Shareholder | Buy | 9,200 | $2.34 | $21,528.00 | 136,806 | |
| 8/20/2015 | Yoram Bibring | CFO | Buy | 8,500 | $3.04 | $25,840.00 | 50,000 | |
| 8/17/2015 | Yoram Bibring | CFO | Buy | 41,500 | $2.92 | $121,180.00 | | |
| 10/10/2014 | International Holdings Ltd Acc | Major Shareholder | Buy | 8,600 | $4.06 | $34,916.00 | | |
| 10/1/2014 | International Holdings Ltd Acc | Major Shareholder | Buy | 6,700 | $4.14 | $27,738.00 | | |
| 9/22/2014 | International Holdings Ltd Acc | Major Shareholder | Buy | 11,000 | $4.17 | $45,870.00 | | |
| 9/15/2014 | Anthony S Fiorino | CEO | Buy | 18,000 | $0.28 | $5,040.00 | | |
| 6/16/2014 | International Holdings Ltd Acc | Major Shareholder | Buy | 130,000 | $0.29 | $37,700.00 | | |
| 6/13/2014 | International Holdings Ltd Acc | Major Shareholder | Buy | 150,000 | $0.35 | $52,500.00 | | |
| 4/28/2014 | International Holdings Ltd Acc | Major Shareholder | Buy | 939,600 | $0.30 | $281,880.00 | | |
(Data available from 1/1/2013 forward)
Brainstorm Cell Therapeutics (NASDAQ BCLI) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | BCLI: Enrollment in Phase 3 Trial of NurOwn® Continuing on Schedule
finance.yahoo.com - May 17 at 6:41 PM |
 | Brainstorm Cell Therapeutics (BCLI) Upgraded at ValuEngine
www.americanbankingnews.com - May 16 at 3:55 PM |
| Brainstorm Cell Therapeutics (BCLI) Receives New Coverage from Analysts at HC Wainwright
www.americanbankingnews.com - May 15 at 1:19 PM |
 | BrainStorm Cell Therapeutics' (BCLI) CEO Chaim Lebovits on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 14 at 5:20 PM |
| What Should Investors Know About Brainstorm Cell Therapeutics Inc’s (NASDAQ:BCLI) Future?
finance.yahoo.com - May 14 at 5:20 PM |
| Brainstorm Cell Therapeutics (BCLI) PT Set at $9.00 by Maxim Group
www.americanbankingnews.com - May 14 at 3:04 PM |
| Brainstorm Cell Therapeutics (BCLI) Issues Quarterly Earnings Results, Beats Expectations By $0.20 EPS
www.americanbankingnews.com - May 14 at 10:18 AM |
| BrainStorm Announces First Quarter 2018 Financial Results and Provides Corporate and Clinical Highlights
finance.yahoo.com - May 14 at 8:26 AM |
| Brainstorm to Announce First Quarter Financial Results and Provide Corporate Update on Monday, May 14
finance.yahoo.com - May 8 at 8:16 AM |
| Brainstorm Cell Therapeutics (BCLI) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - May 7 at 3:14 AM |
| Analysts Anticipate Brainstorm Cell Therapeutics (BCLI) Will Post Earnings of -$0.14 Per Share
www.americanbankingnews.com - May 4 at 3:20 AM |
 | BrainStorm Cell Therapeutics to Participate in Movement Disorder Panel at the Neurotech Investing and Partnering ...
www.prnewswire.com - May 2 at 8:20 AM |
| BrainStorm Cell Therapeutics to Participate in Movement Disorder Panel at the Neurotech Investing and Partnering Conference
finance.yahoo.com - May 1 at 5:18 PM |
 | Global Translational Regenerative Medicine Market 2018-2023 - CAGR to Grow at 12.5% - ResearchAndMarkets.com
www.businesswire.com - April 28 at 5:14 PM |
| BrainStorm Cell Therapeutics to Present at ARM's 6th Annual Cell & Gene Therapy Investor Day, April 17 in New York
finance.yahoo.com - April 19 at 8:16 AM |
| Brokerages Anticipate Brainstorm Cell Therapeutics (BCLI) to Announce -$0.14 EPS
www.americanbankingnews.com - April 16 at 11:10 PM |
| Brainstorm Cell Therapeutics (BCLI) Upgraded to Hold at ValuEngine
www.americanbankingnews.com - April 3 at 6:58 PM |
| Analysts Anticipate Brainstorm Cell Therapeutics (BCLI) to Post -$0.14 EPS
www.americanbankingnews.com - March 31 at 1:16 AM |
 | Brainstorm Cell Therapeutics (BCLI) Announces Phase 3 Trial of NurOwn in ALS Now Open to Canadian Patients
www.streetinsider.com - March 28 at 5:19 PM |
| Brainstorm Cell Therapeutics (BCLI) Given a $9.00 Price Target by Maxim Group Analysts
www.americanbankingnews.com - March 28 at 10:58 AM |
| BrainStorm Cell Therapeutics' Phase 3 Trial of NurOwn® in ALS Now Open to Canadian Patients
finance.yahoo.com - March 28 at 8:27 AM |
| Brainstorm Cell Therapeutics (BCLI) Presents At The Wall Street Investor Forum 26th Annual Growth Conference - Slideshow
seekingalpha.com - March 26 at 5:18 PM |
| Brainstorm Cell Therapeutics (BCLI) Earns Buy Rating from Maxim Group
www.americanbankingnews.com - March 21 at 2:51 PM |
| BrainStorm Appoints Two Leading Thought Leaders in the Fields of Neuroscience and Regenerative Medicine to its ... - PR Newswire (press release)
www.prnewswire.com - March 21 at 8:48 AM |
| BrainStorm Appoints Two Leading Thought Leaders in the Fields of Neuroscience and Regenerative Medicine to its Scientific Advisory Board
finance.yahoo.com - March 21 at 8:48 AM |
| Insider Buying: Brainstorm Cell Therapeutics (BCLI) Director Purchases 5,700 Shares of Stock
www.americanbankingnews.com - March 20 at 2:32 PM |
| Insider Buying: Brainstorm Cell Therapeutics (BCLI) COO Buys 5,000 Shares of Stock
www.americanbankingnews.com - March 20 at 1:25 PM |
| Brainstorm Cell Therapeutics (BCLI) Downgraded to "Sell" at ValuEngine
www.americanbankingnews.com - March 19 at 11:48 PM |
| ValuEngine Upgrades Brainstorm Cell Therapeutics (BCLI) to "Hold"
www.americanbankingnews.com - March 18 at 8:16 PM |
| Brainstorm Cell Therapeutics Inc (BCLI) to Post Q1 2018 Earnings of ($0.14) Per Share, Zacks Investment Research Forecasts
www.americanbankingnews.com - March 16 at 8:52 AM |
| BrainStorm Cell Therapeutics to Present at the BIO Asia International Conference and the Wall Street Investor Forum - PR Newswire (press release)
www.prnewswire.com - March 16 at 8:19 AM |
| BrainStorm Cell Therapeutics to Present at the BIO Asia International Conference and the Wall Street Investor Forum
finance.yahoo.com - March 15 at 6:12 PM |
| BCLI: Phase 3 Trial in ALS Enrolling Patients
finance.yahoo.com - March 13 at 7:17 PM |
| BrainStorm Cell Therapeutics' (BCLI) CEO Chaim Lebovits on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 11 at 8:14 AM |
| Maxim Group Analysts Give Brainstorm Cell Therapeutics (BCLI) a $9.00 Price Target
www.americanbankingnews.com - March 8 at 9:24 PM |
| Brainstorm Cell Therapeutics (BCLI) Announces Quarterly Earnings Results
www.americanbankingnews.com - March 8 at 9:58 AM |
| BrainStorm Announces Operational Highlights and Financial Results for the Year Ended December 31, 2017 - PR Newswire (press release)
www.prnewswire.com - March 8 at 8:23 AM |
| Brainstorm Cell Therapeutics Inc. to Host Earnings Call
finance.yahoo.com - March 8 at 8:23 AM |
| BrainStorm Announces Operational Highlights and Financial Results for the Year Ended December 31, 2017
finance.yahoo.com - March 8 at 8:23 AM |
| Brainstorm Cell Therapeutics (BCLI) Scheduled to Post Quarterly Earnings on Thursday
www.americanbankingnews.com - March 6 at 9:19 AM |
| BrainStorm to Host an Annual Financial Results Call and Provide a Corporate Update on Thursday, March 8
finance.yahoo.com - March 5 at 8:17 AM |
| Brokerages Expect Brainstorm Cell Therapeutics Inc (BCLI) Will Post Earnings of -$0.09 Per Share
www.americanbankingnews.com - February 24 at 11:14 PM |
| ALS patients are unhappy with how $115 million raised by the Ice Bucket Challenge is being spent
finance.yahoo.com - February 14 at 9:43 AM |
| Corvus Pharmaceuticals (CRVS) versus Brainstorm Cell Therapeutics (BCLI) Head-To-Head Review
www.americanbankingnews.com - February 11 at 8:10 AM |
| Brainstorm Cell Therapeutics (BCLI) Names Anthony Polverino PhD ... - StreetInsider.com
www.streetinsider.com - February 5 at 3:40 PM |
| Brainstorm Cell Therapeutics (BCLI) Names Anthony Polverino PhD ... - StreetInsider.com
www.streetinsider.com - February 5 at 3:40 PM |
| Brainstorm Cell Therapeutics (BCLI) Names Anthony Polverino PhD to Board
www.streetinsider.com - February 5 at 9:34 AM |
| BrainStorm Cell Therapeutics Appoints Senior Kite Executive, Anthony Polverino, Ph.D., to Board of Directors
finance.yahoo.com - February 5 at 9:34 AM |
| Brainstorm Cell Therapeutics (BCLI) versus Its Peers Critical Comparison
www.americanbankingnews.com - January 12 at 1:18 AM |
| Analyzing Brainstorm Cell Therapeutics (BCLI) and Its Competitors
www.americanbankingnews.com - January 9 at 1:42 PM |
Brainstorm Cell Therapeutics (NASDAQ:BCLI) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Income Statement, Balance Sheet and Cash Flow Statement
Brainstorm Cell Therapeutics (NASDAQ BCLI) Stock Chart for Sunday, May, 20, 2018
Loading chart…
